News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It was posted that on Feb. 5th 'The SEC is in the process of obtaining court approval for the distribution....once authorization from the court is obtained, checks will start to be distributed'.
The SEC Distribution plan was submitted to the Court on 9th June 2016 and the Court gave it's approval of that distribution plan on 16th June 2016. Hopefully, the Court will again move surprisingly quickly to approve the distribution!
A while ago someone posted that the expected distribution was in the region of 50%, but 50% of what?
At least our Biozoom shares will not have crashed in this week's market downturn 
ever hopeful....
|
Followers
|
26
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3118
|
|
Created
|
03/02/13
|
Type
|
Free
|
| Moderators | |||
Biozoom is dedicated to the advancement of reflection spectroscopy as a commercial technology. Today's Biozoom technology can be used by anyone, anywhere, as a health and wellness diagnostic tool. The company is constantly researching new applications and innovations.
The Biozoom scanner is the result of more that eight years of investigation, innovation, engineering and collaboration. This remarkable handheld unit is used in concert with Biozoom’s equally sophisticated and medically validated analytical algorithms. At the press of a button, the scanner collects and sends spectroscopic data to Biozoom’s servers, which instantly returns biofeedback to the user.
The founders of Biozoom have been engaged in developing cutting edge optics since 2004. Over the past several years, the founders were involved in a variety of ventures, each dedicated to evolving the efficacy and practical use of optical scanners. Working with European telecom giant Vodafone, the founders developed an application for two-way remote telemedicine through cellular phone devices. In 2007, they undertook an engineering and development partnership with Carl Zeiss, which succeeded in miniaturizing the optical system considerably. After a period of grant-supported research and development, Biozoom's executive management established the company in 2013 to bring this extraordinary technology to the market.
http://biozoom.net
Whether you’re a doctor or a patient, using the Biozoom Biofeedback Scanner to measure blood chemistry levels is as easy as 1-2-3:
1. Hold the palm-sized Biozoom Scanner against the skin.
2. Press a button.
3. Read the results on your smart phone, tablet, laptop, or PC screen.
Biozoom is fast: the analysis takes only 16 milliseconds. And it’s completely noninvasive. No blood samples are required. And there is no puncturing of the skin.
The Biozoom Scanner uses a beam of light to detect and measure antioxidant levels … vitamins … oxidative stress … and cyotochrom oxidase, a critical enzyme that aids in the production of energy in your cells.
The noninvasive optical scanner also measures VO2 max, the maximum amount of oxygen your body can use in one minute per kilogram of body weight – an indicator of your body’s endurance for physical activity.
Planned upgrades to the Biozoom device will enable measurement of blood alcohol, cholesterol, drugs, chronic venous insufficiency, blood pressure, smoke poisoning, and oxygen saturation HbO2.
The Biozoom Scanner is also being developed to be calibrated to measure blood sugar levels – an essential daily test for diabetics that currently requires a pin-prick with a sharp needle. The cost of treating diabetes in the United States is $220 billion a year.
Whether you’re a doctor or a patient, using the Biozoom Biofeedback Scanner to measure blood chemistry levels is as easy as 1-2-3:
1. Hold the palm-sized Biozoom Scanner against the skin.
2. Press a button.
3. Read the results on your smart phone, tablet, laptop, or PC screen.
Biozoom is fast: the analysis takes only 16 milliseconds. And it’s completely noninvasive. No blood samples are required. And there is no puncturing of the skin.
The Biozoom Scanner uses a beam of light to detect and measure antioxidant levels … vitamins … oxidative stress … and cyotochrom oxidase, a critical enzyme that aids in the production of energy in your cells.
The noninvasive optical scanner also measures VO2 max, the maximum amount of oxygen your body can use in one minute per kilogram of body weight – an indicator of your body’s endurance for physical activity.
Planned upgrades to the Biozoom device will enable measurement of blood alcohol, cholesterol, drugs, chronic venous insufficiency, blood pressure, smoke poisoning, and oxygen saturation HbO2.
The Biozoom Scanner is also being developed to be calibrated to measure blood sugar levels – an essential daily test for diabetics that currently requires a pin-prick with a sharp needle. The cost of treating diabetes in the United States is $220 billion a year.
MAYBE you’re old enough to remember Dr. Leonard “Bones” McCoy, the surgeon aboard the U.S.S. Enterprise starship from the original “Star Trek” TV series.
During a field mission, when a crew member was ill, Dr. McCoy used a “tricorder” – a tiny handheld medical diagnostic instrument – to read the patient’s vital signs in seconds. And he didn’t have to take a blood sample or puncture the skin with a needle to do it.
Well, now a technology company that recently went public – Biozoom, Inc. (BIZM) www.biozoom.net – has developed a real-life tricorder: the Biozoom Biofeedback Scanner.
The Biozoom Biofeedback Scanner is the only handheld diagnostic device of its kind worldwide that tests for your health WITHOUT blood tests or piercing your skin.
But the Biozoom Scanner, developed in partnership with Carl Zeiss and Vodafone (VOD), isn’t science fiction. It exists now. Units have already been built and used by doctors in hospital settings – with gratifying results. The product will soon be available to other health care professionals and the general public.
That means you’ll be able to monitor your blood chemistry at home – in seconds – without having your blood drawn through a needle at a diagnostic lab, and then waiting 3 to 5 days for the results. Or paying a big lab bill for the test.
The Biozoom Biofeedback Scanner has already been successfully tested on 1,200 patients. And the next generation of the device is being developed to revolutionize many areas of medicine ranging from biofeedback and oxidative stress to blood pressure and diabetes.
Already in development is a nanotechnology version of the Biozoom scanner technology. The apparatus will be miniaturized to the size of a microchip, enabling Biozoom’s biofeedback scanning capability to be integrated into smartphones and virtually any other small consumer device. Annual nanotechnology revenues are forecast to reach $1 trillion by 2015.
Whether you’re a doctor or a patient, using the Biozoom Biofeedback Scanner to measure blood chemistry levels is as easy as 1-2-3:
1. Hold the palm-sized Biozoom Scanner against the skin.
2. Press a button.
3. Read the results on your smart phone, tablet, laptop, or PC screen.
Biozoom is fast: the analysis takes only 16 milliseconds. And it’s completely noninvasive. No blood samples are required. And there is no puncturing of the skin.
The Biozoom Scanner uses a beam of light to detect and measure antioxidant levels … vitamins … oxidative stress … and cyotochrom oxidase, a critical enzyme that aids in the production of energy in your cells.
The noninvasive optical scanner also measures VO2 max, the maximum amount of oxygen your body can use in one minute per kilogram of body weight – an indicator of your body’s endurance for physical activity.
Planned upgrades to the Biozoom device will enable measurement of blood alcohol, cholesterol, drugs, chronic venous insufficiency, blood pressure, smoke poisoning, and oxygen saturation HbO2.
The Biozoom Scanner is also being developed to be calibrated to measure blood sugar levels – an essential daily test for diabetics that currently requires a pin-prick with a sharp needle. The cost of treating diabetes in the United States is $220 billion a year.
